The emergence of compounds like copyright and Semaglutide signifies a major shift in how we approach metabolic disorders. These groundbreaking therapies belong to a class known as GLP-1 receptor agonists, which replicate the effects of a natural hormone that regulates blood sugar levels and appetite. First, developed for diabetic conditions, their